T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical Cancer Research

• Publication date

  2002-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 12006508
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of CD8+ T‐cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide

  2000cited by this paper
• Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3‐lactone‐KLH conjugate plus immunological adjuvant QS‐21

  2000cited by this paper
• Role of Antigen-Presenting Cells in Mediating Tolerance and Autoimmunity

  2000cited by this paper
• Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.

  1999cited by this paper
• Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells.

  1999cited by this paper
• A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma.

  1999cited by this paper
• Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression.

  1999cited by this paper
• Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1

  1999cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998influential reference
• Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.

  1998cited by this paper
• Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes

  1998cited by this paper
• Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

  1997cited by this paper
• Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.

  1996cited by this paper
• Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.

  1996cited by this paper
• The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.

  1996cited by this paper
• Immunological Memory and Protective Immunity: Understanding Their Relation

  1996cited by this paper
• Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo

  1996cited by this paper
• Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

  1996cited by this paper
• Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens

  1996influential reference
• GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.

  1995cited by this paper
• Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes

  1994cited by this paper
• Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.

  1994cited by this paper
• Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

  1994cited by this paper
• Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity.

  1993cited by this paper
• Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.

  1992cited by this paper
• Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.

  1992cited by this paper
• Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing

  1992cited by this paper
• Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex.

  1991cited by this paper
• Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice.

  1991cited by this paper
• A purified saponin acts as an adjuvant for a T-independent antigen.

  1991cited by this paper
• Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response.

  1991cited by this paper

• Activated T cell therapy targeting glioblastoma cancer stem cells

  2023cites this paper
• AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence

  2020cites this paper
• Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment

  2020cites this paper
• Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors

  2019cites this paper
• Present status and future perspective of peptide‐based vaccine therapy for urological cancer

  2018cites this paper
• Polyactin A is a novel and potent immunological adjuvant for peptide‐based cancer vaccine☆

  2018cites this paper
• Melanoma antigens and related immunological markers.

  2017cites this paper
• IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.

  2016cites this paper
• Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma

  2016influential citation
• Molecular and functional analysis of the tumour antigen T21

  2015cites this paper
• Circulation but Not in the Tumor Site T Cells in the + Melanoma-Specific CD8 New Generation Vaccine Induces Effective

  2015cites this paper
• A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites

  2015cites this paper
• Newer developments in the immunotherapy of malignant melanoma

  2014cites this paper
• Peptide-based vaccines for cancer therapy

  2014cites this paper
• Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.

  2014cites this paper
• with Potent Antitumor Properties HLA-A*0201-Binding Epitope of HER-2/neu Identification of a Novel Immunogenic

  2013cites this paper
• myeloma regions of the tumor derived immunoglobulin heavy chain in multiple T-cell epitopes within the complementarity-determining and framework

  2013cites this paper
• Carbohydrate Based Antigens: Potential Tool for A Targeted Immunotherapeutic Approach to Treatment of Metastatic Breast Cancer

  2013cites this paper
• Minimalistic immunologically defi ned gene expression T helper cell 1 (MIDGE-Th1 ® ) vectors coding for Inter- leukin 12 and -18 in combination with the transfection agent SAINT-18 have systemic antitumoral effects on equine melanomas

  2012cites this paper
• Tumor-Specific Antigens and Immunologic Adjuvants in Cancer Immunotherapy

  2011cites this paper
• ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.

  2011cites this paper
• Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumors.

  2011cites this paper
• Immunotherapy for Melanoma: Current Status and Perspectives

  2010cites this paper
• A Myeloid Cell Population Induced by Freund Adjuvant Suppresses T-cell−mediated Antitumor Immunity

  2010cites this paper
• When gene therapy meets adoptive cell therapy: better days ahead for cancer immunotherapy?

  2010cites this paper
• Cancer vaccine strategies and studies of human thioredoxin reductase splice variants

  2010cites this paper
• Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma.

  2010cites this paper
• ÉVALUATION DES PROTEINES MIDKINE ET SURVIVINE SUREXPRIMEES DANS LES CELLULES TUMORALES COMME CIBLES DE L'IMMUNITE CELLULAIRE ANTI-TUMORALE

  2009cites this paper
• Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.

  2009cites this paper
• Potent Antitumor Properties neu HLA-A * 0201-Binding Epitope of HER-2 / Identification of a Novel Immunogenic

  2008cites this paper
• Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma

  2008cites this paper
• The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.

  2008cites this paper
• A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression

  2008cites this paper
• Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

  2008cites this paper
• Optimal dose and schedule of an HER‐2/neu (E75) peptide vaccine to prevent breast cancer recurrence

  2008cites this paper
• Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen

  2008cites this paper
• Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties1

  2008cites this paper
• Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.

  2008cites this paper
• Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients

  2008cites this paper
• Combined ClinicalTrial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute ClinicalTrials Group Study I-01and I-02

  2008cites this paper
• Vaccines as Targeted Cancer Therapy

  2008cites this paper
• A strategy for efficient cross-presentation of CTL-epitope peptides leading to enhanced induction of in vivo tumor immunity.

  2007cites this paper
• Immunological Adjuvant Effect of Ginsenoside Rh4 from the Roots of Panax notoginseng on Specific Antibody and Cellular Response to Ovalbumin in Mice

  2007cites this paper
• Phase I Clinical Study With Multiple Peptide Vaccines in Combination With Tetanus Toxoid and GM-CSF in Advanced-stage HLA-A*0201-positive Melanoma Patients

  2007cites this paper
• Novel antibodies as anticancer agents

  2007cites this paper
• Vaccine Targeted to Her-2 / ErbB2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor Challenge

  2007cites this paper
• A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge.

  2007cites this paper
• Induction of multiple CD8+ T cell responses against the inducible Hsp70 employing an Hsp70 oligoepitope peptide.

  2007cites this paper
• Immunomodulatory Molecules of the Immune System

  2007cites this paper
• Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.

  2007cites this paper
• Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes.

  2007cites this paper
• Properties and Architecture of Drugs and Natural Products Revisited

  2007cites this paper
• Melanoma cancer vaccines and anti‐tumor T cell responses

  2007cites this paper
• Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.

  2007cites this paper
• A Phase I Study of the Optimized Cryptic Peptide TERT572Y in Patients with Advanced Malignancies

  2006cites this paper
• Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma

  2006cites this paper
• Malignant melanoma--clinical development of peptide-based melanoma vaccines.

  2006cites this paper
• The human T cell response to melanoma antigens.

  2006cites this paper
• Immunological adjuvant effect of Glycyrrhiza uralensis saponins on the immune responses to ovalbumin in mice.

  2006cites this paper
• Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.

  2006cites this paper
• Immunomodulatory adjuvants from Quillaja saponaria

  2006cites this paper
• New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site1

  2006cites this paper
• Ginsenoside Re and Notoginsenoside R1: Immunologic Adjuvants with Low Haemolytic Effect

  2006cites this paper
• Human T cell responses against melanoma.

  2006cites this paper
• Adjuvant effect of Achyranthes bidentata saponins on specific antibody and cellular response to ovalbumin in mice.

  2006cites this paper
• Haemolytic Activity and Adjuvant Effect of Notoginsenoside K from the Roots of Panax notoginseng

  2006cites this paper
• Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines

  2006cites this paper
• Effects of QS-21 on Innate and Adaptive Immune Responses

  2006cites this paper
• Handbook of ELISPOT

  2005influential citation
• Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.

  2005cites this paper
• Bioactive saponins with cancer related and immunomodulatory activity: Recent developments

  2005cites this paper
• Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity

  2005cites this paper
• Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma

  2005cites this paper
• Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

  2005influential citation
• Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

  2005cites this paper
• Antigen specific active immunotherapy: lessons from the first decade.

  2005cites this paper
• Active Antigen-specific Immunotherapy of Melanoma: from Basic Science to Clinical Investigation

  2005cites this paper
• A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)

  2005cites this paper
• Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

  2005cites this paper
• High resolution as a key feature to perform accurate ELISPOT measurements using Zeiss KS ELISPOT readers.

  2005cites this paper
• Cancer immunotherapy targeting Sp17: When should the laboratory findings be translated to the clinics?

  2005cites this paper
• Current vaccine adjuvants: an overview of a diverse class.

  2004influential citation
• Immune responses against spontaneous tumors in a murine model for pancreatic adenocarcinoma

  2004cites this paper
• Peptide-based vaccines for cancer immunotherapy

  2004cites this paper
• T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?

  2004cites this paper
• A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.

  2004cites this paper
• Phenotypic and Functional Maturation of Tumor Antigen-Reactive CD8+ T Lymphocytes in Patients Undergoing Multiple Course Peptide Vaccination

  2004cites this paper
• Anticancer vaccination strategies.

  2004cites this paper
• Immunological monitoring of cancer vaccine therapy

  2004cites this paper
• Dendritic cells: a journey from laboratory to clinic

  2004cites this paper
• Communicated by : LJ Old Ex vivo detectable activation of MelanA-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA

  2004cites this paper
• Granulocyte-Macrophage Colony Stimulating Factor: An Adjuvant for Cancer Vaccines

  2004cites this paper
• Evaluation of Elispot assays: influence of method and operator on variability of results.

  2004cites this paper
• B-Raf specific antibody responses in melanoma patients

  2004cites this paper
• Ex Vivo Analysis of Human Antigen-Specific CD8+ T-Cell Responses: Quality Assessment of Fluorescent HLA-A2 Multimer and Interferon-γ ELISPOT Assays for Patient Immune Monitoring

  2004cites this paper
• Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

  2004influential citation
• The current role of systemic therapy in the management of Malignant Melanoma of the skin: a literature review

  2004cites this paper
• Approches thérapeutiques innovantes dans le mélanome New therapeutic approachs in melanoma

  2004cites this paper
• Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

  2004cites this paper
• Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.

  2003cites this paper